Tema Oncology ETF (NASDAQ:CANC) Short Interest Up 453.8% in February

Tema Oncology ETF (NASDAQ:CANC) was the recipient of a large increase in short interest in February. As of February 28th, there was short interest totalling 7,200 shares, an increase of 453.8% from the February 13th total of 1,300 shares. Based on an average daily volume of 19,700 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.3% of the shares of the stock are sold short.

Tema Oncology ETF Stock Up 1.3 %

Shares of CANC stock traded up $0.33 during trading hours on Wednesday, reaching $25.07. The company’s stock had a trading volume of 7,377 shares, compared to its average volume of 11,148. Tema Oncology ETF has a fifty-two week low of $23.97 and a fifty-two week high of $30.11. The company has a market capitalization of $63.93 million, a price-to-earnings ratio of 26.86 and a beta of 1.11. The firm’s 50 day simple moving average is $25.18 and its 200-day simple moving average is $26.78.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Tema Oncology ETF stock. Thrivent Financial for Lutherans lifted its holdings in Tema Oncology ETF (NASDAQ:CANC) by 29.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 517,837 shares of the company’s stock after acquiring an additional 118,328 shares during the period. Thrivent Financial for Lutherans owned approximately 20.31% of Tema Oncology ETF worth $13,156,000 as of its most recent filing with the Securities and Exchange Commission.

About Tema Oncology ETF

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.